Example: marketing
IN THIS ISSUE

IN THIS ISSUE

Back to document page

Highmark Blue Shield has established preferred product for rituximab. The preferred product for rheumatoid arthritis (RA) indications is rituximab- pvvr (Ruxience) when the clinical criteria within the policy are met. This revised Medical Policy will apply to professional providers and facility claims. The effective date is April 1, 2022.

  Medical, Blue, Shield, Highmark, Highmark blue shield

Download IN THIS ISSUE


Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Related search queries